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Abstract
Background: Infection with the Gram-negative bacterium Burkholderia pseudomallei is an important cause of community-
acquired lethal sepsis in endemic regions in southeast Asia and northern Australia and is increasingly reported in other
tropical areas. In animal models, production of interferon-gamma (IFN-c) is critical for resistance, but in humans the
characteristics of IFN-c production and the bacterial antigens that are recognized by the cell-mediated immune response
have not been defined.
Methods: Peripheral blood from 133 healthy individuals who lived in the endemic area and had no history of melioidosis, 60
patients who had recovered from melioidosis, and 31 other patient control subjects were stimulated by whole bacteria or
purified bacterial proteins in vitro, and IFN-c responses were analyzed by ELISPOT and flow cytometry.
Findings: B. pseudomallei was a potent activator of human peripheral blood NK cells for innate production of IFN-c.I n
addition, healthy individuals with serological evidence of exposure to B. pseudomallei and patients recovered from active
melioidosis developed CD4
+ (and CD8
+) T cells that recognized whole bacteria and purified proteins LolC, OppA, and PotF,
members of the B. pseudomallei ABC transporter family. This response was primarily mediated by terminally differentiated T
cells of the effector–memory (TEMRA) phenotype and correlated with the titer of anti-B. pseudomallei antibodies in the serum.
Conclusions: Individuals living in a melioidosis-endemic region show clear evidence of T cell priming for the ability to make
IFN-c that correlates with their serological status. The ability to detect T cell responses to defined B. pseudomallei proteins in
large numbers of individuals now provides the opportunity to screen candidate antigens for inclusion in protein or
polysaccharide–conjugate subunit vaccines against this important but neglected disease.
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Introduction
Melioidosis is a serious infectious disease in Southeast Asia and
Northern Australia caused by the soil-dwelling Gram-negative
bacterium, Burkholderia pseudomallei [1]. In Northeast Thailand, the
mortality rate for acute melioidosis remains high, approximately
50%, despite recent advances in antibiotic treatments. Serological
evidence, based on the indirect hemagglutination assay (IHA),
suggests that 80% of people living in endemic areas have been
exposed to B. pseudomallei, without showing clinical symptoms [1–
3]. Recurrent melioidosis can also occur either as relapse after
antibiotic treatment or re-infection [3,4]. B. pseudomallei is classified
as a NIAID category B potential agent for biological terrorism [5].
The mechanism that enables the organism to avoid the
bactericidal effects of the host immune response has never been
fully understood, and there are no licensed vaccines.
B. pseudomallei is able to disseminate throughout the body,
invades non-phagocytic cells and replicates in phagocytes [6,7]. In
mice, B. pseudomallei is a potent inducer of IFN-c and IFN-c
inducing cytokines such as IL-12, IL-18 and TNF in vitro and IFN-
c is essential for resistance in vivo via the activation of macrophages
for both oxygen dependent and independent killing mechanisms
[8]. In mice, NK cells and bystander CD8
+ T cells provide innate
production of IFN-c [9], while IFN-c secreting, antigen-specific
CD4
+ T cells contribute to protection against primary infection
with B. pseudomallei and following immunization with experimental
vaccines in vivo [10,11]. In addition, murine models of vaccination
with dendritic cells pulsed with heat killed B. pseudomallei in the
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of protection [12] suggesting the role of specific T cells in host
protection.
In contrast, the mechanisms of cell-mediated immunity to B.
pseudomallei in humans are poorly understood. IFN-c, IL-12, IL-18
and TNF are found in plasma samples from acute, septic
melioidosis but the IFN-c producing cells have not been well
characterized [13]. Previous studies in small numbers of patients in
northern Australia and Papua New Guinea who recovered from
melioidosis have demonstrated evidence of T cell priming to B.
pseudomallei, but the characteristics of the responding cell
populations and the antigens recognized have not been defined
[14,15].
Here, we analyzed a large cohort of individuals from the
melioidosis endemic region of Thailand to identify the cellular
sources of IFN-c in response to whole B. pseudomallei and the
bacterial ABC transporter proteins LolC, OppA and PotF which
are T cell immunogens in mice and candidate vaccine antigens
[16,17]. Peripheral blood cells from healthy individuals with
serological evidence of exposure to B. pseudomallei and recovered
melioidosis patients (but not seronegative control subjects) showed
evidence of CD4 and CD8 T cell priming to both whole bacteria
and purified B. pseudomallei antigens. Together with a prominent
IFN-c response from NK cells, these sources of IFN-c may
contribute to host resistance against melioidosis in the endemic
setting.
Materials and Methods
The study and the consent forms were approved by the Khon
Kaen University Ethics Committee for Human Research (Project
number HE470506). Informed consent was obtained from all the
subjects recruited into the study.
Blood samples
Blood samples from 133 healthy donors who had no clinical
history of melioidosis were collected at the Blood Bank, Khon
Kaen University, Thailand. Another set of blood samples was
obtained from patients and control subjects at Sappasithiprasong
Hospital, Thailand for cellular studies by ELISPOT assay. Patients
were defined as those who had recovered from melioidosis
(previously diagnosed by isolation of B. pseudomallei from blood
or tissues) and completed antibiotic treatment (n=36). Non
infected control subjects (n=21) were those who attended the
hospital for non infectious reasons at the diabetic clinic and had no
history of clinical melioidosis, and were matched for age, sex,
occupation, the presence of diabetes as an underlying condition
and lived in the same endemic area. In addition, 24 recovered
melioidosis patients and 10 healthy control subjects were enrolled,
using the same criteria, at Srinagarind Hospital, Thailand for
cellular sources of IFN-c, kinetics and memory cells assayed by
flow cytometry. The subjects who had antibodies to B. pseudomallei
at a titer of 1:40 or greater by IHA were considered seropositive
[15,18]. None of the subjects had any clinical sign or symptoms of
any infection including HIV/AIDS at the time of blood collection.
In vitro cell stimulation
B. pseudomallei strain K96243 is a clinical isolate from Thailand
and is the prototype genome sequence strain [19]. Whole heat-
killed B. pseudomallei (hkBp) was prepared by heating the bacteria at
100uC for 20 minutes, washed twice with PBS pH 7.4, aliquoted
and stored at 280uC. The number of viable bacteria was
determined by colony-forming counts and defined as colony-
forming units (CFU) prior to heating. Recombinant B. pseudomallei
ABC transporter proteins (LolC, OppA and PotF) were prepared
as previously described [16,17] and used as test stimulators in this
study. Phytohemagglutinin (PHA) (Biochrom AG, Germany),
human recombinant IL-12, and IL-15 (BD Biosciences, USA)
and a MHC class I-restricted T cell epitope control of pooled
peptides of cytomegalovirus, Epstein Barr virus and influenza virus
(CEF) were used as positive controls (Mabtech, AB, Sweden).
Recombinant protein from Francisella tularensis, FT1823 [20] was
included as a non related protein/negative control.
Enzyme-linked immunospot assay (ELISPOT) for human
IFN-c
Peripheral blood mononuclear cells (PBMCs) from each subject
were isolated from heparinized blood samples by density
centrifugation on Ficoll-Hypaque and adjusted the number of
cells as required prior to stimulation. In brief, 96-well PVDF-plates
(MSIP, Millipore) were previously coated overnight with 15 mg/ml
1D1K anti-human IFN-c at 4uC. Fresh PBMCs were added in
duplicate wells at 5610
5 PBMCs/well and each stimulator was
added at the optimal concentration. After 42 hours, secreted IFN-
c was detected by adding 1 mg/ml biotinylated mAb 7-B6-1-biotin
for IFN-c for 3 hours and followed by 1 mg/ml streptavidin-
alkaline phosphatase (Mabtech, AB, Sweden) prior to enumeration
under a stereomicroscope. The responses were compared in the
absence or presence of 0.3 mg/ml cyclosporin A (CsA, Sigma,
USA).
Intracellular cytokine staining assay by flow cytometry
Whole blood samples were firstly analyzed for complete blood
count using an automatic machine (Sysmex, Germany). The
number of absolute lymphocytes was then adjusted to 9610
5
lymphocytes/ml by diluting with completed RPMI medium (10%
FBS supplement). The adjusted cells in 100 ml were added into 96
well culture plates and added up by another 100 mlo f2 6
concentration of stimulators and incubated at 37uC with 5% CO2.
Cultured cells were blocked with 10 mg/ml brefeldin A (Sigma,
Author Summary
The Gram-negative bacterium, Burkholderia pseudomallei,
is a public health problem in southeast Asia and northern
Australia and a Centers for Disease Control and Prevention
listed Category B potential bioterrorism agent. It is the
causative agent of melioidosis, and clinical manifestations
vary from acute sepsis to chronic localized and latent
infection, which can reactivate decades later. B. pseudo-
mallei is the major cause of community-acquired pneu-
monia and septicemia in northeast Thailand. In spite of the
medical importance of B. pseudomallei, little is known
about the mechanisms of pathogenicity and the immu-
nological pathways of host defense. There is no available
vaccine, and the mortality rate in acute cases can exceed
40% with 10–15% of survivors relapsing or being
reinfected despite prolonged and complete treatments.
In this article, we describe cell-mediated immune respons-
es to B. pseudomallei in humans living in northeast
Thailand and demonstrate clear evidence of T cell priming
in healthy seropositive individuals and patients who
recovered from melioidosis. This is the most detailed
study yet performed on the cell types that produce
interferon-gamma to B. pseudomallei in humans and the
antigens that they recognize and the first to study large
sample numbers in the primary endemic focus of
melioidosis in the world.
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washed and blocked with anti-CD16 (BD Biosciences). The
following antibodies were used for immune cell surface staining:
FITC anti-CD4, PE anti-CD8 or PE anti-CD56 (BD Biosciences)
and Tricolor anti-CD3 (Invitrogen, USA). In addition, cell surface
markers for memory T cell phenotypes were included: FITC anti-
CCR7 (R&D systems, USA), PE anti-CD45RA (Invitrogen) and
Tricolor anti-CD4 or CD8 (Invitrogen). Isotype-matched control
antibodies were used in each analysis. After 30 min of staining,
followed by fixation with 10% paraformaldehyde-PBS overnight at
room temperature, cells were then permeabilized by 0.12%
saponin (Sigma, USA) for 15 min followed by APC anti-IFN-c
(Invitrogen, USA) for 30 min prior to analysis by FACScalibur
with CELLQuest software (BD Biosciences, USA).
Statistical analysis
Statistical analysis (one way-ANOVA, unpaired and paired t-
test) was performed using Graphpad Prism version 5 software
(GraphPad, San Diego, CA, USA). A P-value,0.05 was
considered statistically significant.
Results
Cellular immune responses to B. pseudomallei of healthy
individuals living in an endemic area of melioidosis
To examine the cellular immune response to B. pseudomallei of
healthy individuals living in Northeast Thailand, PBMCs of 133
donors from the Blood Bank at Khon Kaen University, Thailand
were cultured with whole bacteria, recombinant B. pseudomallei
ABC transporter proteins (LolC, OppA and PotF) or control
stimulators and 42 hours later assayed for IFN-c production by
ELISPOT. We have previously shown in mice that several
different cell types contribute to IFN-c responses to B. pseudomallei
in vitro; NK cells and bystander T cells produce IFN-c indirectly
via a cytokine mediated pathway which is not blocked by
cyclosporin A (CsA), whereas specific B. pseudomallei primed T
cells respond via a CsA sensitive T cell receptor (TCR) dependent
process [9,11]. To validate this approach in human peripheral
blood, we initially compared the CsA sensitivity of cytokine (IL-
12+IL-15), mitogen (PHA) or antigen specific IFN-c responses in
vitro in the presence or absence of CsA. Compared to medium
alone controls, cells incubated with PHA or a pooled cocktail of
established T cell reactive peptides from pathogens known to be
present in the Thai population (CMV, EBV and influenza) showed
strong IFN-c responses which were inhibited in the presence of
CsA (Figure 1A; P,0.0001, paired t-test). In contrast, the IFN-c
response to IL-12/IL-15 or the low but detectable background
response observed in cells incubated with an irrelevant Francisella
tularensis control protein were not CsA susceptible. Moreover, the
results revealed that whole B. pseudomallei (hkBp) and three Bp-
derived ABC transporter proteins (LolC, OppA and PotF) could
induce IFN-c responses via TCR independent (innate) and
dependent (specific) pathways in healthy individuals in vitro
(Figure 1B).These IFN-c responses were in a dose dependent
manner ranging between 1610
4–1610
7 CFU/ml hkBp and 0.1–
3.0 mg/ml of the 3 proteins (data not shown).
Specific T cell responses to B. pseudomallei correlate with
serological evidence of exposure to the bacterium
IHA has been widely used as routine serologic test for
melioidosis with the threshold titer of 1:40 in the endemic area
indicating previous exposure to B. pseudomallei [15,18]. To
investigate whether the magnitude of the cellular immune
response correlated with evidence of exposure to B. pseudomallei
by serology, 133 healthy donors were classified into five groups
based on their B. pseudomallei antibody IHA titers (as 1:20, 1:40,
1:180, 1:160 and 1:320 (n=6, 19, 60, 45 and 3, respectively;
Figure 2). The results revealed that the continual increase of the
average values of specific (CsA sensitive) IFN-c spots in response to
B. pseudomallei and its proteins was significantly correlated with
increasing antibody titers (P,0.0001, one way ANOVA). No such
correlation was observed in the response to CEF vs. medium
controls or for the innate (CsA resistant) IFN-c spots to B.
pseudomallei (P.0.05, one way ANOVA). Thus environmental
Figure 1. IFN-c responses to B. pseudomallei of 133 healthy individuals living in Northeast Thailand. PBMCs of healthy blood donors
were stimulated with whole bacteria, recombinant Bp proteins and control stimulators for 42 hours in vitro and IFN-c secreting cells were
enumerated by ELISPOT. IFN-c spot forming cells (SFC) per 1610
6 PBMCs in response to (A) control stimulators including medium alone (M),
cytokines (1 mg/ml IL-12 plus IL-15), 1.25 mg/ml PHA, 2 mg/ml pooled viral peptides (CEF) and 1 mg/ml non related protein of F. tularensis (FT) and (B)
IFN-c responses to 3610
6 CFU/ml heat killed B. pseudomallei (hkBp), 1 mg/ml ABC transporter proteins of B. pseudomallei (LolC, OppA and PotF). IFN-c
spots were enumerated in the absence (closed circles) and presence (crossed) of 0.3 mg/ml cyclosporin A (CsA). Horizontal lines represent the mean
value of each group, *** P,0.0001, ns-non statistical significance (paired t-test).
doi:10.1371/journal.pntd.0000407.g001
Human Cellular Immunity to B. pseudomallei
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generates both T cell and B cell responses to B. pseudomallei in
healthy individuals even in the absence of disease.
Cellular immune responses to B. pseudomallei in patients
recovered from melioidosis
To assess the extent of T cell priming in patients who had
survived active infection, specific T cell responses to whole
bacteria and recombinant proteins of B. pseudomallei were studied
in 36 recovered melioidosis cases and 21 other patient control
subjects from the same endemic region chosen on the basis of same
age, sex and occupation with no history of clinical melioidosis but
who were seropositive for B. pseudomallei exposure. The frequency
of IFN-c producing cells was significantly increased in recovered
patients compared to seronegative control subjects (data not
shown) but was similar to that observed in seropositive healthy
individuals (Figure 3A) (P.0.05, unpaired t-test). However, there
were some individuals who had no specific IFN-c producing cells
to B. pseudomallei above the background of medium control in both
groups. Of note, IFN-c levels as quantified by ELISA were
significantly higher in recovered melioidosis patients than
seropositive individuals (Figure S1). According to Figure 3B, the
comparison of IFN-c responses between patients who recovered
from melioidosis with a history of localized infection (n=13) and
severe sepsis (n=11) did not show any significant difference. These
specific T cell responses declined over the time but remained
detectable after 80 weeks (Figure 3C). These results indicated that
either whole B. pseudomallei or its proteins could trigger the cellular
immune response following re-exposure to the microorganism in
vitro up to 80 weeks post admission.
Diabetes mellitus (DM) is a major risk factor for human
melioidosis [21], and only 4 cases of recovered melioidosis without
DM were found in this study. Even though we observed no
difference between IFN-c responses of these groups, it remains
inconclusive for the effect of diabetic condition on host T cell
responses (data not shown). In addition, recovered melioidosis
patients with a history of recurrent infection (n=6) compared to
those with a single disease episode (n=30) also showed no
statistically significant difference (data not shown); suggesting that
under these conditions IFN-c responses do not differentiate
between primary and recurrent melioidosis.
Cellular sources and kinetics of IFN-c in response to B.
pseudomallei
To identify the cellular sources of IFN-c responses to B.
pseudomallei, whole blood samples from six seropositive healthy
individuals and ten recovered melioidosis cases (all with IHA
antibodies 1:40 or greater) were restimulated with B. pseudomallei in
the absence of CsA and analyzed by four-color flow cytometry. As
shown from one representative of seropositive group, the small
lymphocyte area was gated (Figure 4A) and analysis of IFN-c
+ cells
showed that NK cells (CD3
2CD56
+), CD4
+ T (CD3
+CD4
+) and
CD8
+ T (CD3
+CD8
+) cells all contributed to IFN-c production to
hkBp (Figure 4B). A dominant contribution of CD4
+ and CD8
+ T
Figure 2. Distribution of specific T cell responses to whole B. pseudomallei and three ABC transporter proteins. PBMCs from 133 healthy
blood donors as described in Figure 1 were classified according to plasma IHA antibody titers; 1:20, 1:40, 1:80, 1:160 and 1:320 (n=6, 19, 60, 45 and 3,
respectively) and analyzed for specific (CsA sensitive) IFN-c secreting spots assayed by ELISPOT in response to medium alone, 2 mg/ml pool viral
peptides (CEF), whole B. pseudomallei (hk Bp) and Bp derived ABC transporter proteins (LolC, OppA and PotF). *** P,0.0001, ns-non statistical
significance (one way ANOVA).
doi:10.1371/journal.pntd.0000407.g002
Human Cellular Immunity to B. pseudomallei
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of specific IFN-c (CsA sensitive) spots following depletion of CD3,
CD4 and/or CD8 cells (Figure S2). In addition, the mean
fluorescent intensities (MFI) of intracellular IFN-gamma staining
of CD3
+ and CD3
2 (NK) cells of 4 recovered melioidosis cases
were analyzed and revealed that the average MFI of IFN-gamma
gated on CD3
+ cells was significantly higher than CD3
2 (NK) cells
(P,0.05, paired t-test) (Figure S3). Together with our finding that
the ELISPOT size of remaining IFN-c
+ cells after T cell depletion
was very small suggests that innate (CsA resistant) cells produce
less of this cytokine compared to specific T cells.
The analysis of blood samples from 6 seropositive individuals
and 10 recovered melioidosis cases showed background staining of
total IFN-c producing cells in medium alone at 0.0360.01 and
0.360.09% (mean6SE), respectively. The relative contribution of
each cell type to the IFN-c response to B. pseudomallei also varied
according to the time point examined in culture after addition of
the bacteria. NK cells appeared to respond more rapidly than T
cells and significantly contributed to the production of rapid IFN-c
at 4 hours and decreased over time in both groups (Figure 5). On
the one hand, the frequency of IFN-c producing NK cells were
significantly higher in seropositive healthy individuals than
recovered melioidosis at 4 and 12 hours (P,0.05, unpaired t-
test). On the other hand, there was a statistically significant
difference of IFN-c producing CD4
+ T cells being higher in
recovered melioidosis than the seropositive individuals at both
time points and all three time points for IFN-c producing CD8
+ T
cells. These results demonstrated the increasing contribution to
IFN-c production over the time from T cell subsets, particularly in
the recovered melioidosis group.
Rapid responses of memory phenotype T cells to whole
B. pseudomallei
To investigate whether the rapid IFN-c producing T cells in
response to B. pseudomallei were memory T-cell phenotypes,
immune subsets of human memory T cells were identified based
on the cell surface expression of CD45RA and CCR7 [22] in 16
recovered melioidosis cases and 7 seropositive control subjects.
The results demonstrated the percentages of IFN-c producing
memory T cells and the majority of memory CD4
+ and CD8
+ T
cells of both groups were revealed as terminally differentiated T
effector memory (TEMRA) cells which was significantly higher than
the other memory phenotypes of effector memory (TEM) and
central memory (TCM) cells of CD4
+ and CD8
+ T cells (P,0.0001,
unpaired t-test) (Figure 6A).
When the clinical histories of these 16 recovered melioidosis
subjects were analyzed, distinctive patterns of memory T cell
phenotypes were revealed. The memory T cells of the septicemic
melioidosis group (n=12) were TEMRA significantly greater than
TEM and TCM of both CD4
+ and CD8
+ subsets (P,0.0001,
unpaired t-test). Interestingly, there was a trend of localized
melioidosis group (n=4) showed stronger responses of TEMRA
with small contribution of TCM cells and TEM cells, but it was not
statistically significant (Figure 6B).
Figure 3. Specific T cell responses to B. pseudomallei of
recovered melioidosis cases vs. seropositive control subjects.
(A) Specific (CsA sensitive) IFN-c secreting spots in response to medium
alone, whole B. pseudomallei and Bp-derived ABC transporter proteins,
LolC, OppA and PotF were analyzed from 36 recovered melioidosis
cases (R) and 21 seropositive control subjects (S+). (B) Of these 36
recovered melioidosis cases, only 24 cases were analyzed according to
the previous history of localized melioidosis (LR, n=13) and septicemic
melioidosis (SR, n=11) and (C) the time of sample collection (weeks)
after completion of antibiotic treatments of recovered melioidosis
cases. Horizontal lines represent mean6SE value of each group.
Medium alone of recovered melioidosis and seropositive control
groups was less than 5 IFN-c SFC/10
6 PBMCs.
doi:10.1371/journal.pntd.0000407.g003
Human Cellular Immunity to B. pseudomallei
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Burkholderia pseudomallei is an important cause of community
acquired sepsis and death in endemic regions of SE Asia and
Northern Australia and is listed as potential bioterrorism threat.
Yet despite its current and potential impact on public health our
understanding of immune defenses against this pathogen are
incomplete. B. pseudomallei is capable of extensive extracellular
growth and abscess formation, but is also genetically adapted to
survive and replicate within host cells [6,23]. It is killed by IFN-c
activated macrophages in vitro [24], making cell mediated
immunity a potentially important component of resistance. Here,
a total of 224 individuals living in the endemic area of NE
Thailand of varying immunological and clinical history for
exposure to B. pseudomallei were examined for the magnitude and
characteristics of their IFN-c responses following restimulation of
whole blood with whole bacteria or B. pseudomallei derived antigens
in vitro.
Northeast Thailand is the primary endemic focus of melioidosis
in SE Asia and the majority of individuals show evidence of
Figure 4. Identification of IFN-c secreting T cells responding to whole B. pseudomallei by four-color flow cytometry. Whole blood
samples from eight recovered melioidosis cases and six seropositive control subjects were incubated with whole B. pseudomallei for 12 hours and
stained for intracellular IFN-c vs. three immune cell surface markers (Tri-color anti-CD3, FITC-anti-CD4 and PE-anti-CD8 or PE-anti-CD56). The profile
from one representative donor of seropositive control subjects, (A) gated on lymphocyte cells, and (B) gated on IFN-c
+ cells.
doi:10.1371/journal.pntd.0000407.g004
Human Cellular Immunity to B. pseudomallei
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of the diversity of the IFN-c response in this setting, blood samples
from 133 randomly selected individuals who had no clinical
history of melioidosis were tested for reactivity to B. pseudomallei by
IFN-c ELISPOT. The majority showed clear induction of IFN-c
positive cells above that of medium alone controls in the presence
of whole bacteria. Addition of cyclosporin A (CsA) which
specifically inhibits T cell receptor-mediated but not cytokine
mediated lymphocyte activation [9,11,25] showed this response
was made up of both innate and adaptive IFN-c responses. To
further define the adaptive IFN-c component, we compared the
frequency of CsA sensitive IFN-c producing cells against the
antibody titer of each individual. Serological evidence of exposure
to B. pseudomallei is clinically determined by an indirect
hemagglutination (IHA) assay which mostly detects antibodies to
conserved lipopolysaccharides and/or capsular polysaccharides
and is useful in diagnosis of melioidosis particularly in non or low
endemic areas [1]. Although the threshold IHA titer for
serodiagnosis varies in different countries, in the Northeast Thai
population; an IHA titer 1:40 is considered to be indicative of
previous exposure to B. pseudomallei in healthy individuals [15,18].
The frequency of specific, B. pseudomallei induced IFN-c cells
closely correlated with the serological status of the donor, whereas
no such correlation was observed with control antigens derived
from viruses known to be prevalent in the Thai population. Thus
environmental exposure to B. pseudomallei induces concordant
adaptive T and B cell responses as also seen in other examples of
infection or vaccination [26,27].
In mice, IFN-c is critical for survival of the infected host and
NK cells, as well as both CD4
+ and CD8
+ T cells contribute to its
production [9,10]. Using intracellular cytokine staining and
specific cell depletion we found a similar situation in humans in
which all three cell types produced IFN-c in vitro, with their
relative contribution differing according to the serological status of
the host. An initial finding was that human NK cells were
prominent producers of IFN-c in vitro, providing some 80% of the
IFN-c positive cells in the first few hours of the culture period. This
response was observed in both seronegative and seropositive
individuals, was not inhibited by CsA and most likely represents an
innate response to the bacterium presumably driven via the
generation of IFN-c inducing cytokines such as IL-12, IL-15 and
IL-18 in culture [9,28]. This observation may also explain the
previous findings by Lauw et al of a rapid IFN-c dependent
induction of the chemokines Mig and IP-10 in whole blood
cultures of healthy individuals in the presence of dead B.
pseudomallei [29].
In seropositive individuals, this innate response was supple-
mented by the presence of IFN-c positive CD4
+ T cells and CD8
+
Figure 5. Kinetics of IFN-c producing cells from ten recovered melioidosis cases and six seropositive control subjects in response to
B. pseudomallei in vitro. Whole blood samples were incubated with whole B. pseudomallei for 4, 12 and 24 hours and stained for intracellular IFN- c
vs. three immune cell surface markers (Tri-color anti-CD3, FITC-anti-CD4 and PE-anti-CD8 or PE-anti-CD56). (A) Distribution of individual responses,
horizontal lines indicate mean6SE values of the group and (B) the relative contribution of CD4, CD8 and NK cells to produce IFN- c of ten recovered
melioidosis cases (R) vs. six seropositive control subjects (S+), gated on IFN-c
+ cells. * P,0.05, ** P,0.005, ns-non significant (unpaired t-test).
doi:10.1371/journal.pntd.0000407.g005
Human Cellular Immunity to B. pseudomallei
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healthy control subjects. A predominance of CD4
+ T cells was
observed from the peripheral blood of recovered melioidosis
subjects. Haque A, et al. also reported that antigen-specific CD4
+
T cells were important for the resistance against B. pseudomallei
during the later phase of primary infection [10]. Clear evidence of
priming of CD8
+ T cells was also observed, presumably reflecting
the cytoplasmic habitat of the bacterium within host cells [14].
These antigen specific T cells provided the majority of the total
IFN-c generated in culture as evidenced by their higher mean
fluorescent intensities (MFI) of IFN-c staining (Figure S3), larger
ELISPOT sizes (data not shown) and by the significant effect of T
cell depletion on the IFN-c ELISPOT response. Of note, we have
compared T cell responses by the production of IFN-c vs.
granzyme B by ELISPOT and the results showed high correlation
of these 2 indicators in response to B. pseudomallei suggesting the
importance of cytotoxic T cell response in melioidosis (Figure S4).
However, the role of these cells to combat this intracellular
pathogen requires further studies.
We then used differential expression of CD45RA and CCR7 to
characterize the IFN-c producing T cells as either central memory
(CM), effector memory (EM) or a more recently described effector
memory RA (EMRA) populations [30–32]. By these criteria,
.80% of IFN-c
+ CD4
+ T cells and .90% of IFN-c
+ CD8
+ T cells
reacting to B. pseudomallei were TEMRA cells, with the remaining
minority being TCM and TEM cells. Thus, B. pseudomallei
predominately induces ‘effector memory RA’ T cells in the
peripheral blood that respond rapidly to repeated exposure to the
microorganism as also reported with other pathogens such as
human cytomegalovirus and human immunodeficiency virus
[31,33]. There was a trend towards a greater contribution of
TEM and TCM cells in patients with a history of septicemia
compared to localized melioidosis but this did not attain statistical
significance and further studies using larger cohort sizes are
needed to confirm this.
Several earlier reports established that exposure to B. pseudomallei
primed human T cells for proliferation and secretion of the
macrophage activating cytokine IFN-c in vitro. However, these
studies were restricted to small numbers of individuals in Northern
Australia and Papua New Guinea and did not define the
frequencies, memory phenotypes of the responding cell popula-
tions or the antigen specificity of these responses. The results
presented here confirm and extend these findings to a larger
sample size in the endemic region of Thailand. A consistent
finding in all studies are that T cell responses were greater in
seropositive versus seronegative individuals. With the larger group
sizes provided in the Thai population we can go further and show
that this also correlates with antibody titer, and not simply
between antibody positive versus negative status. What is less clear
is the relative strength of the cell mediated responses between
seropositive healthy donors and recovered patients. Barnes et al
found that lymphocyte proliferation and IFN-c production was
greater in seropositive healthy donors (n=8) than those recovered
from infection (n=5), arguing as in the case of tuberculosis, of
impaired immunity in those who experienced clinical disease [13].
However, our results in the Thai population showed no difference
in the frequencies of IFN-c producing cells in the recovered
melioidosis group versus seropositive healthy donors, although
both were clearly greater than seronegative control subjects. In
contrast, the amount of IFN-c secreted (as determined by ELISA)
and the frequency of high IFN-c responders was greater in the
recovered group suggesting an increased immune priming
following a significant bacterial burden compared to healthy
exposed control subjects. Of note, even with the larger sample
sizes used here, IFN-c responses were similar between individuals
with and without diabetes, in patients with septicemic versus
localized disease or in cases of recurrent versus single episodes of
disease [4].
Given the high mortality of acute melioidosis and the problems
of treatment, the development of an effective vaccine is an
Figure 6. Memory phenotypes of IFN-c producing cells from recovered melioidosis cases vs. seropositive healthy control subjects
in response to B. pseudomallei in vitro. Whole blood samples were incubated with whole B. pseudomallei for 12 hours and stained for intracellular
IFN- c vs. three immune cell surface markers (Tri-color anti-CD4 or CD8, FITC-anti-CCR7 and PE-anti-CD45RA), gated on IFN-c
+ cells. The distribution of
memory phenotype subsets i.e., central memory (TCM, CD45RA
2CCR7
+), effector memory (TEM, CD45RA-CCR7
2) and terminally differentiated T
effector memory (TEMRA, CD45RA
+CCR7
2) of (A) 16 recovered melioidosis (R) vs. 7 seropositive individuals (S+), (B) recovered melioidosis with the
history of septicemic (SR, n=12) vs. localized (LR, n=4) melioidosis. Horizontal lines indicate mean6SE values of the group.
doi:10.1371/journal.pntd.0000407.g006
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living in endemic areas as well as in situations of accidental or
purposeful exposure following a bioterrorism scenario. Experi-
mental strategies using wild type bacteria of reduced virulence
[34], live attenuated mutants of B. pseudomallei [23,35] and killed
whole cells [12] have all been attempted with varying success.
However, one important approach requires identification of
individual B. pseudomallei specific proteins, which are both
immunogenic and protective, for inclusion in protein and/or
polysaccharide sub-unit based vaccines [36–38]. To date, the
number of B. pseudomallei proteins which have been defined as T
cell immunogens in mice or humans is very limited [38–40]. In
other pathogenic bacteria, ABC transporter proteins have roles in
bacterial survival, virulence and pathogenicity, are immunogenic
in humans and an increasing number are being considered as
candidate vaccine antigens [41–43]. We have previously shown
that three members of the bacterial ABC transporter family, LolC,
PotF and OppA are immunogenic in mice and particularly in the
case of LolC provide at least partial protection against lethal
challenge with B. pseudomallei following immunization in adjuvant
[17]. We now show that all three proteins are recognized by T
cells from seropositive individuals and could be considered for
future vaccine development. No T cell response was observed in B.
pseudomallei seronegative individuals, arguing that these antigens
are relatively specific for B. pseudomallei and priming is not the
result of cross reactivity against other common bacterial infections
in the community.
In conclusion, we provide here the mostextensive study to date of
the human cell mediated immune response to B. pseudomallei and the
first to define this aspect of immunity in Thailand, the major
endemic focus of melioidosis in the world. Our data demonstrate
that B. pseudomallei specific CD4
+ T cells secreting IFN-c are
generated following exposure to the bacterium in the environment
and the magnitude of this cellular response correlates with the
serological status of the individual. Our findings that NK cells and
CD8
+ T cells also provide a potential source of IFN-c, may help to
explain the apparent lack of impact of HIV/AIDS on the incidence
of melioidosis in Thailand. Our ability to detect specific T cell
responses to defined B. pseudomallei proteins in large numbers of
individuals now provides the opportunity to screen candidate
antigens for inclusion in protein or protein-polysaccharide conju-
gate subunitvaccines against this important and emerging infection.
Supporting Information
Alternative Language Abstract S1 Translation of the Abstract
into Thai by Jirawan Mahawantung and Ganjana Lertmemong-
kolchai
Found at: doi:10.1371/journal.pntd.0000407.s001 (0.09 MB PDF)
Figure S1 Quantification of IFN-c production from recovered
melioidosis cases vs. seropositive healthy control subjects in
response to B. pseudomallei in vitro. Whole blood samples from 14
seronegative (S2), 29 seropositive (S+) healthy and 29 recovered
melioidosis (R) individuals were incubated with medium alone,
1610
6 CFU/ml whole B. pseudomallei, 10 ng/ml IL-12+IL-15 and
1.25 mg/ml PHA for 42 hours and collected cultured supernatants
for quantitative IFN-c analysis by ELISA. Horizontal lines
indicate mean6SE values of the group, * P,0.05, ns-non
significant (unpaired t-test).
Found at: doi:10.1371/journal.pntd.0000407.s002 (0.10 MB PDF)
Figure S2 Immune cell depletion and specific IFN-c secreting
spots in response to hkBp and its ABC transporter proteins. CD3,
CD4 and/or CD8 cells were depleted from PBMCs of a
seropositive healthy donor by immunomagnetic beads prior to
stimulation (ELISPOT details as in Figure 1). Percentage (%) of
specific (CsA sensitive) IFN-c response after depletion was
compared to the response of total PBMCs. Data show mean6S.E.
Found at: doi:10.1371/journal.pntd.0000407.s003 (0.09 MB PDF)
Figure S3 Mean fluorescent intensities of IFN-c produced by
CD3
+ vs. NK cells in response to B. pseudomallei. Whole blood
samples of 4 recovered melioidosis were incubated with hkBp for
12 hours and stained for intracellular IFN-c vs. immune cell
surface markers, details as in Figure 4. (A) The mean fluorescent
intensity of IFN-c staining cells analyzed by histograms of medium
(grey) overlayered with hkBp (black line) stimulated CD3
+ vs. NK
cells, (B) distribution and mean6S.E of MFI of 4 recovered
melioidosis (panel B). * P,0.05 (paired t-test).
Found at: doi:10.1371/journal.pntd.0000407.s004 (0.08 MB PDF)
Figure S4 Correlation of IFN-c vs. granzyme B production by
specific T cells in responses to whole B. pseudomallei and three ABC
transporter proteins. PBMCs from 54 healthy blood donors were
determined for IFN-c vs. granzyme B by ELISPOT as described
in Figure 1 (r
2=correlation coefficient).
Found at: doi:10.1371/journal.pntd.0000407.s005 (0.10 MB PDF)
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